Clinical Trial Search

Primary: Incidence and Severity of Ocular Adverse Events (AEs) — 1; 3; 2; 1 participants

Primary: Estimated Glomerular Filtration Rate (eGFR) — -0.66; -0.32 ml/min/month — p=0.01

Primary: All-cause Mortality Through Day 42 — 18.6; 20.2 percentage of participants

Primary: the Cases of Adverse Events With Participant Injection of ESAT6-CFP10 — 3; 1; 0; 0 cases

Primary: Proportion of Infants With a HR ≥ 100 Bpm at 2 Minutes of Life. — 93.7; 88; 93 percentage of participants

Primary: Healing Defined as a Decrease in Ulcer Area by at Least 25% of the Initial Area — 24; 78 percentage of healed ulcers — p=0.05

Primary: Amount of New Bone Mass Formed — 89 percentage of bone formation

Primary: Percentage of Participants With Booster Responses Against Polio Antigens Following Vaccination With IMOVAX POLIO® — 78.0; 78.0; 79.7 Percentage of participants

Primary: Intraabdominal Distance (Centimeters) — 9.3; 9.0 centimeters — p=<0.05

Primary: Percentage of Participants With Progression-free Survival at Week 52 — 22.5 Percentage of participants

Primary: Percentage of Participants With a Psoriasis Area and Severity Index (PASI)75 Response at Week 16 — 33.33; 64.44; 66.29; 74.42 Percentage of participants — p=0.001

Primary: Complete Hematologic Response — 16 participants

Primary: Overview of Treatment-emergent All Causalities Adverse Events (AEs) in Escalation Phase — 14; 6; 7; 6 participants

Primary: Mean Level of Diindolylmethane in Prostate Tissue After Treatment — 14.2 ng/g

Primary: Dose Limiting Toxicity of Bendamustine Hydrochloride and Lenalidomide in Combination With Dexamethasone (Phase I) — 0; 1; 0; 0 Dose Limiting Toxic Events